Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Wooin Lee

Showing results (31-40 of 99) with videos related to

Pageof 10
Sort By:
Journal of Pharmaceutical Sciences|November 7, 2020
Transient, Tunable Expression of NTCP and BSEP in MDCKII Cells for Kinetic Delineation of the Rate-Determining Process and Inhibitory Effects of Rifampicin in Hepatobiliary Transport of TaurocholateSumito Ito, Wooin Lee, Ji Eun Park, et al.
Journal of Pharmaceutical Sciences|October 15, 2020
Improved Prediction of the Drug-Drug Interactions of Pemafibrate Caused by Cyclosporine A and Rifampicin via PBPK Modeling: Consideration of the Albumin-Mediated Hepatic Uptake of Pemafibrate and Inhibition Constants With Preincubation Against OATP1BJi Eun Park, Yoshihisa Shitara, Wooin Lee, et al.
Scientific Reports|March 13, 2019
H727 cells are inherently resistant to the proteasome inhibitor carfilzomib, yet require proteasome activity for cell survival and growthMin Jae Lee, Zachary Miller, Ji Eun Park, et al.
CPT: Pharmacometrics & Systems Pharmacology|August 18, 2019
Expanded Physiologically-Based Pharmacokinetic Model of Rifampicin for Predicting Interactions With Drugs and an Endogenous Biomarker via Complex Mechanisms Including Organic Anion Transporting Polypeptide 1B InductionRyuta Asaumi, Karsten Menzel, Wooin Lee, et al.
The Journal of Pharmacology and Experimental Therapeutics|August 28, 2015
Polymer micelle formulations of proteasome inhibitor carfilzomib for improved metabolic stability and anticancer efficacy in human multiple myeloma and lung cancer cell linesLin Ao, Derek Reichel, Di Hu, et al.
Biomaterials|July 27, 2018
Surface modification of polymer nanoparticles with native albumin for enhancing drug delivery to solid tumorsHyesun Hyun, Joonyoung Park, Kiela Willis, et al.
Small (Weinheim an Der Bergstrasse, Germany)|March 24, 2018
A Comparative In Vivo Study of Albumin-Coated Paclitaxel Nanocrystals and AbraxaneJoonyoung Park, Ji Eun Park, Victoria E Hedrick, et al.
CPT: Pharmacometrics & Systems Pharmacology|January 26, 2018
Comprehensive PBPK Model of Rifampicin for Quantitative Prediction of Complex Drug-Drug Interactions: CYP3A/2C9 Induction and OATP Inhibition EffectsRyuta Asaumi, Kota Toshimoto, Yoshifusa Tobe, et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals|February 25, 2018
Physiologically Based Pharmacokinetic Modeling of Bosentan Identifies the Saturable Hepatic Uptake As a Major Contributor to Its Nonlinear PharmacokineticsMasanobu Sato, Kota Toshimoto, Atsuko Tomaru, et al.
Journal of Pharmaceutical and Biomedical Analysis|August 16, 2015
The identification of lobeglitazone metabolites in rat liver microsomes and the kinetics of the in vivo formation of the major metabolite M1 in ratsJong-Hwa Lee, Sung Hoon Ahn, Han-Joo Maeng, et al.
Pageof 10

Showing results (31-40 of 99) with videos related to

Sort By:
Pageof 10
Journal of Pharmaceutical Sciences|November 7, 2020
Transient, Tunable Expression of NTCP and BSEP in MDCKII Cells for Kinetic Delineation of the Rate-Determining Process and Inhibitory Effects of Rifampicin in Hepatobiliary Transport of TaurocholateSumito Ito, Wooin Lee, Ji Eun Park, et al.
Journal of Pharmaceutical Sciences|October 15, 2020
Improved Prediction of the Drug-Drug Interactions of Pemafibrate Caused by Cyclosporine A and Rifampicin via PBPK Modeling: Consideration of the Albumin-Mediated Hepatic Uptake of Pemafibrate and Inhibition Constants With Preincubation Against OATP1BJi Eun Park, Yoshihisa Shitara, Wooin Lee, et al.
Scientific Reports|March 13, 2019
H727 cells are inherently resistant to the proteasome inhibitor carfilzomib, yet require proteasome activity for cell survival and growthMin Jae Lee, Zachary Miller, Ji Eun Park, et al.
CPT: Pharmacometrics & Systems Pharmacology|August 18, 2019
Expanded Physiologically-Based Pharmacokinetic Model of Rifampicin for Predicting Interactions With Drugs and an Endogenous Biomarker via Complex Mechanisms Including Organic Anion Transporting Polypeptide 1B InductionRyuta Asaumi, Karsten Menzel, Wooin Lee, et al.
The Journal of Pharmacology and Experimental Therapeutics|August 28, 2015
Polymer micelle formulations of proteasome inhibitor carfilzomib for improved metabolic stability and anticancer efficacy in human multiple myeloma and lung cancer cell linesLin Ao, Derek Reichel, Di Hu, et al.
Biomaterials|July 27, 2018
Surface modification of polymer nanoparticles with native albumin for enhancing drug delivery to solid tumorsHyesun Hyun, Joonyoung Park, Kiela Willis, et al.
Small (Weinheim an Der Bergstrasse, Germany)|March 24, 2018
A Comparative In Vivo Study of Albumin-Coated Paclitaxel Nanocrystals and AbraxaneJoonyoung Park, Ji Eun Park, Victoria E Hedrick, et al.
CPT: Pharmacometrics & Systems Pharmacology|January 26, 2018
Comprehensive PBPK Model of Rifampicin for Quantitative Prediction of Complex Drug-Drug Interactions: CYP3A/2C9 Induction and OATP Inhibition EffectsRyuta Asaumi, Kota Toshimoto, Yoshifusa Tobe, et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals|February 25, 2018
Physiologically Based Pharmacokinetic Modeling of Bosentan Identifies the Saturable Hepatic Uptake As a Major Contributor to Its Nonlinear PharmacokineticsMasanobu Sato, Kota Toshimoto, Atsuko Tomaru, et al.
Journal of Pharmaceutical and Biomedical Analysis|August 16, 2015
The identification of lobeglitazone metabolites in rat liver microsomes and the kinetics of the in vivo formation of the major metabolite M1 in ratsJong-Hwa Lee, Sung Hoon Ahn, Han-Joo Maeng, et al.
Pageof 10